Related Experiment Video
Updated: Nov 6, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Recent advances in understanding chronic myeloid leukemia: where do we stand?
Rahul Kumar1, Daniela S Krause1,2,3,4,5
1Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, 60596 Frankfurt, Germany.
Remaining leukemic stem cells (LSCs) drive chronic myeloid leukemia (CML) relapse. Understanding LSC vulnerabilities and microenvironment interactions is key to developing novel therapies for treatment-free remission (TFR).
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Leukemic stem cells (LSCs) are critical for chronic myeloid leukemia (CML) persistence and relapse.
- Understanding LSC biology, including signaling pathways and microenvironment influences, is essential for effective CML treatment.
Purpose of the Study:
- To explore the mechanisms behind LSC persistence in CML.
- To identify LSC vulnerabilities for novel therapeutic strategies.
- To investigate factors influencing treatment-free remission (TFR) in CML patients.
Main Methods:
- Immunophenotypic analysis of LSCs.
- Investigation of signaling pathways (autophagy, metabolism, epigenetics).
- Assessment of immune and bone marrow microenvironmental factors.
Main Results:
- LSC persistence is linked to abnormalities in key signaling pathways.
- Extrinsic factors like the immune and bone marrow microenvironments significantly impact LSC behavior.
- These factors modulate therapeutic response and resistance, influencing TFR achievement.
Conclusions:
- Targeting LSC vulnerabilities and microenvironment interactions is crucial for achieving durable treatment-free remission in CML.
- Further research is needed to understand LSC persistence and progression to blast crisis.
More Related Videos
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
Related Concept Videos
Differentiation of Common Myeloid Progenitor Cells
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...